#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Recent Progress of Antiprotozoan Agents
1-1	0-2	2.	_	_	_	_
1-2	3-9	Recent	abstract[1]	new[1]	_	_
1-3	10-18	Progress	abstract[1]	new[1]	_	_
1-4	19-21	of	abstract[1]	new[1]	_	_
1-5	22-35	Antiprotozoan	abstract[1]|abstract|person[3]	new[1]|new|new[3]	_	_
1-6	36-42	Agents	abstract[1]|person[3]	new[1]|new[3]	_	_

#Text=2.1 .
2-1	43-46	2.1	abstract	new	_	_
2-2	47-48	.	_	_	_	_

#Text=Anti-Giardiasis
3-1	49-64	Anti-Giardiasis	abstract	new	ana	5-1

#Text=Giardiasis is caused by the protozoan parasite G. intestinalis ( also known as G. lamblia or G. duodenalis ) .
4-1	65-75	Giardiasis	event	new	coref	6-1
4-2	76-78	is	_	_	_	_
4-3	79-85	caused	_	_	_	_
4-4	86-88	by	_	_	_	_
4-5	89-92	the	animal[8]	new[8]	_	_
4-6	93-102	protozoan	abstract|animal[8]	new|new[8]	coref	6-6
4-7	103-111	parasite	animal[8]	new[8]	_	_
4-8	112-114	G.	_	_	_	_
4-9	115-127	intestinalis	_	_	_	_
4-10	128-129	(	_	_	_	_
4-11	130-134	also	_	_	_	_
4-12	135-140	known	_	_	_	_
4-13	141-143	as	_	_	_	_
4-14	144-146	G.	_	_	_	_
4-15	147-154	lamblia	_	_	_	_
4-16	155-157	or	_	_	_	_
4-17	158-160	G.	_	_	_	_
4-18	161-171	duodenalis	_	_	_	_
4-19	172-173	)	_	_	_	_
4-20	174-175	.	_	_	_	_

#Text=It is also known by the common name “ beaver fever , ” because this infection was reported in campers who drank contaminated water that was inhabited by beavers .
5-1	176-178	It	abstract	giv	_	_
5-2	179-181	is	_	_	_	_
5-3	182-186	also	_	_	_	_
5-4	187-192	known	_	_	_	_
5-5	193-195	by	_	_	_	_
5-6	196-199	the	abstract[10]	new[10]	appos	5-10[12_10]
5-7	200-206	common	abstract[10]	new[10]	_	_
5-8	207-211	name	abstract[10]	new[10]	_	_
5-9	212-213	“	_	_	_	_
5-10	214-220	beaver	animal|abstract[12]	new|giv[12]	_	_
5-11	221-226	fever	abstract[12]	giv[12]	_	_
5-12	227-228	,	_	_	_	_
5-13	229-230	”	_	_	_	_
5-14	231-238	because	_	_	_	_
5-15	239-243	this	abstract[13]	new[13]	_	_
5-16	244-253	infection	abstract[13]	new[13]	_	_
5-17	254-257	was	_	_	_	_
5-18	258-266	reported	_	_	_	_
5-19	267-269	in	_	_	_	_
5-20	270-277	campers	person	new	_	_
5-21	278-281	who	_	_	_	_
5-22	282-287	drank	_	_	_	_
5-23	288-300	contaminated	substance[15]	new[15]	coref	9-14[0_15]
5-24	301-306	water	substance[15]	new[15]	_	_
5-25	307-311	that	_	_	_	_
5-26	312-315	was	_	_	_	_
5-27	316-325	inhabited	_	_	_	_
5-28	326-328	by	_	_	_	_
5-29	329-336	beavers	animal	new	_	_
5-30	337-338	.	_	_	_	_

#Text=Giardiasis is the most common protozoan infection in human beings , and it occurs in both developing and industrialized countries .
6-1	339-349	Giardiasis	abstract	giv	coref	6-3[19_0]
6-2	350-352	is	_	_	_	_
6-3	353-356	the	abstract[19]	giv[19]	ana	6-13[0_19]
6-4	357-361	most	abstract[19]	giv[19]	_	_
6-5	362-368	common	abstract[19]	giv[19]	_	_
6-6	369-378	protozoan	abstract|abstract[19]	giv|giv[19]	coref	8-16[34_0]
6-7	379-388	infection	abstract[19]	giv[19]	_	_
6-8	389-391	in	abstract[19]	giv[19]	_	_
6-9	392-397	human	abstract[19]|person[20]	giv[19]|new[20]	coref	24-27[136_20]
6-10	398-404	beings	abstract[19]|person[20]	giv[19]|new[20]	_	_
6-11	405-406	,	_	_	_	_
6-12	407-410	and	_	_	_	_
6-13	411-413	it	event	giv	ana	7-1
6-14	414-420	occurs	_	_	_	_
6-15	421-423	in	_	_	_	_
6-16	424-428	both	place[22]	new[22]	coref	9-7[38_22]
6-17	429-439	developing	place[22]	new[22]	_	_
6-18	440-443	and	place[22]	new[22]	_	_
6-19	444-458	industrialized	place[22]	new[22]	_	_
6-20	459-468	countries	place[22]	new[22]	_	_
6-21	469-470	.	_	_	_	_

#Text=Its global incidence is believed to range between 20 % – 60 % , with 2 % – 7 % incidence in industrialized nations .
7-1	471-474	Its	event|abstract[24]	giv|new[24]	coref|coref|coref|coref	7-19[29_24]|9-1[37_0]|7-19[29_24]|9-1[37_0]
7-2	475-481	global	abstract[24]	new[24]	_	_
7-3	482-491	incidence	abstract[24]	new[24]	_	_
7-4	492-494	is	_	_	_	_
7-5	495-503	believed	_	_	_	_
7-6	504-506	to	_	_	_	_
7-7	507-512	range	_	_	_	_
7-8	513-520	between	_	_	_	_
7-9	521-523	20	quantity[25]	new[25]	_	_
7-10	524-525	%	quantity[25]	new[25]	_	_
7-11	526-527	–	quantity[25]	new[25]	_	_
7-12	528-530	60	quantity[25]|quantity[26]	new[25]|new[26]	_	_
7-13	531-532	%	quantity[25]|quantity[26]	new[25]|new[26]	_	_
7-14	533-534	,	_	_	_	_
7-15	535-539	with	_	_	_	_
7-16	540-541	2	quantity[27]	new[27]	_	_
7-17	542-543	%	quantity[27]	new[27]	_	_
7-18	544-545	–	quantity[27]	new[27]	_	_
7-19	546-547	7	quantity[27]|quantity[28]|abstract[29]	new[27]|new[28]|giv[29]	_	_
7-20	548-549	%	quantity[27]|quantity[28]|abstract[29]	new[27]|new[28]|giv[29]	_	_
7-21	550-559	incidence	quantity[27]|abstract[29]	new[27]|giv[29]	_	_
7-22	560-562	in	quantity[27]|abstract[29]	new[27]|giv[29]	_	_
7-23	563-577	industrialized	quantity[27]|abstract[29]|place[30]	new[27]|giv[29]|new[30]	_	_
7-24	578-585	nations	quantity[27]|abstract[29]|place[30]	new[27]|giv[29]|new[30]	_	_
7-25	586-587	.	_	_	_	_

#Text=Giardia intestinalis was first described in 1681 after the Dutch microscopist Antonie van Leeuwenhoek observed the protozoan in his own diarrheic stools .
8-1	588-595	Giardia	abstract	new	coref	12-4
8-2	596-608	intestinalis	_	_	_	_
8-3	609-612	was	_	_	_	_
8-4	613-618	first	_	_	_	_
8-5	619-628	described	_	_	_	_
8-6	629-631	in	_	_	_	_
8-7	632-636	1681	time	new	_	_
8-8	637-642	after	_	_	_	_
8-9	643-646	the	person[33]	giv[33]	ana	8-19[0_33]
8-10	647-652	Dutch	person[33]	giv[33]	_	_
8-11	653-665	microscopist	person[33]	giv[33]	_	_
8-12	666-673	Antonie	person[33]	giv[33]	_	_
8-13	674-677	van	person[33]	giv[33]	_	_
8-14	678-689	Leeuwenhoek	person[33]	giv[33]	_	_
8-15	690-698	observed	_	_	_	_
8-16	699-702	the	abstract[34]	giv[34]	_	_
8-17	703-712	protozoan	abstract[34]	giv[34]	_	_
8-18	713-715	in	_	_	_	_
8-19	716-719	his	person|object[36]	giv|new[36]	_	_
8-20	720-723	own	object[36]	new[36]	_	_
8-21	724-733	diarrheic	object[36]	new[36]	_	_
8-22	734-740	stools	object[36]	new[36]	_	_
8-23	741-742	.	_	_	_	_

#Text=This disease is often prevalent in poor countries and communities that have untreated water , inadequate sanitation , and poor dietary status .
9-1	743-747	This	abstract[37]	giv[37]	coref	10-1[44_37]
9-2	748-755	disease	abstract[37]	giv[37]	_	_
9-3	756-758	is	_	_	_	_
9-4	759-764	often	_	_	_	_
9-5	765-774	prevalent	_	_	_	_
9-6	775-777	in	_	_	_	_
9-7	778-782	poor	place[38]	giv[38]	_	_
9-8	783-792	countries	place[38]	giv[38]	_	_
9-9	793-796	and	place[38]	giv[38]	_	_
9-10	797-808	communities	place[38]|organization	giv[38]|new	_	_
9-11	809-813	that	place[38]	giv[38]	_	_
9-12	814-818	have	place[38]	giv[38]	_	_
9-13	819-828	untreated	place[38]	giv[38]	_	_
9-14	829-834	water	place[38]|substance	giv[38]|giv	coref	10-19[49_0]
9-15	835-836	,	place[38]	giv[38]	_	_
9-16	837-847	inadequate	place[38]|substance[41]	giv[38]|new[41]	_	_
9-17	848-858	sanitation	place[38]|substance[41]	giv[38]|new[41]	_	_
9-18	859-860	,	place[38]	giv[38]	_	_
9-19	861-864	and	place[38]	giv[38]	_	_
9-20	865-869	poor	place[38]|abstract[43]	giv[38]|new[43]	_	_
9-21	870-877	dietary	place[38]|abstract|abstract[43]	giv[38]|new|new[43]	_	_
9-22	878-884	status	place[38]|abstract[43]	giv[38]|new[43]	_	_
9-23	885-886	.	_	_	_	_

#Text=The infection is caused by fecal – oral transmission and initiated by the ingestion of infectious cysts from contaminated water or through person-to-person contact .
10-1	887-890	The	abstract[44]	giv[44]	coref	12-4[59_44]
10-2	891-900	infection	abstract[44]	giv[44]	_	_
10-3	901-903	is	_	_	_	_
10-4	904-910	caused	_	_	_	_
10-5	911-913	by	_	_	_	_
10-6	914-919	fecal	substance	new	_	_
10-7	920-921	–	_	_	_	_
10-8	922-926	oral	abstract[46]	new[46]	_	_
10-9	927-939	transmission	abstract[46]	new[46]	_	_
10-10	940-943	and	_	_	_	_
10-11	944-953	initiated	_	_	_	_
10-12	954-956	by	_	_	_	_
10-13	957-960	the	event[47]	new[47]	_	_
10-14	961-970	ingestion	event[47]	new[47]	_	_
10-15	971-973	of	event[47]	new[47]	_	_
10-16	974-984	infectious	event[47]|object[48]	new[47]|new[48]	_	_
10-17	985-990	cysts	event[47]|object[48]	new[47]|new[48]	_	_
10-18	991-995	from	event[47]|object[48]	new[47]|new[48]	_	_
10-19	996-1008	contaminated	event[47]|object[48]|substance[49]	new[47]|new[48]|giv[49]	_	_
10-20	1009-1014	water	event[47]|object[48]|substance[49]	new[47]|new[48]|giv[49]	_	_
10-21	1015-1017	or	_	_	_	_
10-22	1018-1025	through	_	_	_	_
10-23	1026-1042	person-to-person	abstract[50]	new[50]	_	_
10-24	1043-1050	contact	abstract[50]	new[50]	_	_
10-25	1051-1052	.	_	_	_	_

#Text=After excystation , flagellated trophozoites colonize the upper small intestine , where they attach to the epithelial lining but do not invade the mucosa .
11-1	1053-1058	After	_	_	_	_
11-2	1059-1070	excystation	event	new	_	_
11-3	1071-1072	,	_	_	_	_
11-4	1073-1084	flagellated	animal[52]	new[52]	ana	11-13[0_52]
11-5	1085-1097	trophozoites	animal[52]	new[52]	_	_
11-6	1098-1106	colonize	_	_	_	_
11-7	1107-1110	the	place[53]	new[53]	_	_
11-8	1111-1116	upper	place[53]	new[53]	_	_
11-9	1117-1122	small	place[53]	new[53]	_	_
11-10	1123-1132	intestine	place[53]	new[53]	_	_
11-11	1133-1134	,	_	_	_	_
11-12	1135-1140	where	_	_	_	_
11-13	1141-1145	they	animal	giv	_	_
11-14	1146-1152	attach	_	_	_	_
11-15	1153-1155	to	_	_	_	_
11-16	1156-1159	the	place[55]	new[55]	_	_
11-17	1160-1170	epithelial	place[55]	new[55]	_	_
11-18	1171-1177	lining	place[55]	new[55]	_	_
11-19	1178-1181	but	_	_	_	_
11-20	1182-1184	do	_	_	_	_
11-21	1185-1188	not	_	_	_	_
11-22	1189-1195	invade	_	_	_	_
11-23	1196-1199	the	object[56]	new[56]	_	_
11-24	1200-1206	mucosa	object[56]	new[56]	_	_
11-25	1207-1208	.	_	_	_	_

#Text=The duration of Giardia infection is variable ; however , chronic infection and reinfection commonly occur .
12-1	1209-1212	The	abstract[57]	new[57]	_	_
12-2	1213-1221	duration	abstract[57]	new[57]	_	_
12-3	1222-1224	of	abstract[57]	new[57]	_	_
12-4	1225-1232	Giardia	abstract[57]|object|abstract[59]	new[57]|giv|giv[59]	coref|coref|coref|coref	12-11[60_59]|16-6|12-11[60_59]|16-6
12-5	1233-1242	infection	abstract[57]|abstract[59]	new[57]|giv[59]	_	_
12-6	1243-1245	is	_	_	_	_
12-7	1246-1254	variable	_	_	_	_
12-8	1255-1256	;	_	_	_	_
12-9	1257-1264	however	_	_	_	_
12-10	1265-1266	,	_	_	_	_
12-11	1267-1274	chronic	abstract[60]	giv[60]	coref	13-10[0_60]
12-12	1275-1284	infection	abstract[60]	giv[60]	_	_
12-13	1285-1288	and	_	_	_	_
12-14	1289-1300	reinfection	event	new	_	_
12-15	1301-1309	commonly	_	_	_	_
12-16	1310-1315	occur	_	_	_	_
12-17	1316-1317	.	_	_	_	_

#Text=Approximately 50 % of the symptoms classically associated with giardiasis are asymptomatic including diarrhea , abdominal pain , nausea , vomiting , and anorexia .
13-1	1318-1331	Approximately	quantity[62]	new[62]	_	_
13-2	1332-1334	50	quantity[62]	new[62]	_	_
13-3	1335-1336	%	quantity[62]	new[62]	_	_
13-4	1337-1339	of	quantity[62]	new[62]	_	_
13-5	1340-1343	the	quantity[62]|abstract[63]	new[62]|new[63]	_	_
13-6	1344-1352	symptoms	quantity[62]|abstract[63]	new[62]|new[63]	_	_
13-7	1353-1364	classically	_	_	_	_
13-8	1365-1375	associated	_	_	_	_
13-9	1376-1380	with	_	_	_	_
13-10	1381-1391	giardiasis	abstract	giv	coref	16-35[84_0]
13-11	1392-1395	are	_	_	_	_
13-12	1396-1408	asymptomatic	_	_	_	_
13-13	1409-1418	including	_	_	_	_
13-14	1419-1427	diarrhea	abstract	new	coref	24-18
13-15	1428-1429	,	_	_	_	_
13-16	1430-1439	abdominal	abstract[66]	new[66]	coref	24-15[132_66]
13-17	1440-1444	pain	abstract[66]	new[66]	_	_
13-18	1445-1446	,	_	_	_	_
13-19	1447-1453	nausea	_	_	_	_
13-20	1454-1455	,	_	_	_	_
13-21	1456-1464	vomiting	abstract	new	_	_
13-22	1465-1466	,	_	_	_	_
13-23	1467-1470	and	_	_	_	_
13-24	1471-1479	anorexia	abstract	new	_	_
13-25	1480-1481	.	_	_	_	_

#Text=However , infected individuals can also develop extraintestinal and postinfectious complications .
14-1	1482-1489	However	_	_	_	_
14-2	1490-1491	,	_	_	_	_
14-3	1492-1500	infected	person[69]	new[69]	_	_
14-4	1501-1512	individuals	person[69]	new[69]	_	_
14-5	1513-1516	can	_	_	_	_
14-6	1517-1521	also	_	_	_	_
14-7	1522-1529	develop	abstract	new	coref|none	28-6[159_0]|14-7[0_159]
14-8	1530-1545	extraintestinal	abstract[70]	new[70]	_	_
14-9	1546-1549	and	abstract[70]	new[70]	_	_
14-10	1550-1564	postinfectious	abstract[70]	new[70]	_	_
14-11	1565-1578	complications	abstract[70]	new[70]	_	_
14-12	1579-1580	.	_	_	_	_

#Text=Chronic extraintestinal sequelae may affect the joints , skin , eyes , and central nervous system , but the underlying mechanisms are unknown .
15-1	1581-1588	Chronic	abstract[71]	new[71]	_	_
15-2	1589-1604	extraintestinal	abstract[71]	new[71]	_	_
15-3	1605-1613	sequelae	abstract[71]	new[71]	_	_
15-4	1614-1617	may	_	_	_	_
15-5	1618-1624	affect	_	_	_	_
15-6	1625-1628	the	object[72]	new[72]	_	_
15-7	1629-1635	joints	object[72]	new[72]	_	_
15-8	1636-1637	,	_	_	_	_
15-9	1638-1642	skin	object	new	_	_
15-10	1643-1644	,	_	_	_	_
15-11	1645-1649	eyes	object	new	_	_
15-12	1650-1651	,	_	_	_	_
15-13	1652-1655	and	_	_	_	_
15-14	1656-1663	central	place[75]	new[75]	_	_
15-15	1664-1671	nervous	place[75]	new[75]	_	_
15-16	1672-1678	system	place[75]	new[75]	_	_
15-17	1679-1680	,	_	_	_	_
15-18	1681-1684	but	_	_	_	_
15-19	1685-1688	the	abstract[76]	new[76]	_	_
15-20	1689-1699	underlying	abstract[76]	new[76]	_	_
15-21	1700-1710	mechanisms	abstract[76]	new[76]	_	_
15-22	1711-1714	are	_	_	_	_
15-23	1715-1722	unknown	_	_	_	_
15-24	1723-1724	.	_	_	_	_

#Text=According to research data , Giardia has eight distinct genetic assemblages labelled as assemblage “ A ” through “ H ” , and assemblages “ A ” and “ B ” are responsible for infection in humans .
16-1	1725-1734	According	_	_	_	_
16-2	1735-1737	to	_	_	_	_
16-3	1738-1746	research	abstract|abstract[78]	new|new[78]	coref|coref	28-3|28-3
16-4	1747-1751	data	abstract[78]	new[78]	_	_
16-5	1752-1753	,	_	_	_	_
16-6	1754-1761	Giardia	animal	giv	coref	21-23
16-7	1762-1765	has	_	_	_	_
16-8	1766-1771	eight	abstract[80]	new[80]	_	_
16-9	1772-1780	distinct	abstract[80]	new[80]	_	_
16-10	1781-1788	genetic	abstract[80]	new[80]	_	_
16-11	1789-1800	assemblages	abstract[80]	new[80]	_	_
16-12	1801-1809	labelled	_	_	_	_
16-13	1810-1812	as	_	_	_	_
16-14	1813-1823	assemblage	_	_	_	_
16-15	1824-1825	“	person[81]	new[81]	_	_
16-16	1826-1827	A	person[81]	new[81]	_	_
16-17	1828-1829	”	person[81]	new[81]	_	_
16-18	1830-1837	through	person[81]	new[81]	_	_
16-19	1838-1839	“	person[81]	new[81]	_	_
16-20	1840-1841	H	person[81]	new[81]	_	_
16-21	1842-1843	”	person[81]	new[81]	_	_
16-22	1844-1845	,	_	_	_	_
16-23	1846-1849	and	_	_	_	_
16-24	1850-1861	assemblages	object[82]	new[82]	_	_
16-25	1862-1863	“	object[82]	new[82]	_	_
16-26	1864-1865	A	object[82]	new[82]	_	_
16-27	1866-1867	”	object[82]	new[82]	_	_
16-28	1868-1871	and	_	_	_	_
16-29	1872-1873	“	_	_	_	_
16-30	1874-1875	B	place	new	_	_
16-31	1876-1877	”	_	_	_	_
16-32	1878-1881	are	_	_	_	_
16-33	1882-1893	responsible	_	_	_	_
16-34	1894-1897	for	_	_	_	_
16-35	1898-1907	infection	abstract[84]	giv[84]	coref	17-12[0_84]
16-36	1908-1910	in	abstract[84]	giv[84]	_	_
16-37	1911-1917	humans	abstract[84]|person	giv[84]|new	_	_
16-38	1918-1919	.	_	_	_	_

#Text=Three classes of drugs are currently used for the treatment of giardiasis : metronidazole , mepacrine analogs , and nitrofurans , such as furazolidone (
17-1	1920-1925	Three	person[86]	new[86]	_	_
17-2	1926-1933	classes	person[86]	new[86]	_	_
17-3	1934-1936	of	person[86]	new[86]	_	_
17-4	1937-1942	drugs	person[86]|substance	new[86]|new	coref	25-22[142_0]
17-5	1943-1946	are	_	_	_	_
17-6	1947-1956	currently	_	_	_	_
17-7	1957-1961	used	_	_	_	_
17-8	1962-1965	for	_	_	_	_
17-9	1966-1969	the	abstract[88]	new[88]	_	_
17-10	1970-1979	treatment	abstract[88]	new[88]	_	_
17-11	1980-1982	of	abstract[88]	new[88]	_	_
17-12	1983-1993	giardiasis	abstract[88]|abstract	new[88]|giv	coref	20-12
17-13	1994-1995	:	abstract[88]	new[88]	_	_
17-14	1996-2009	metronidazole	abstract[88]|substance	new[88]|new	coref	20-1
17-15	2010-2011	,	abstract[88]	new[88]	_	_
17-16	2012-2021	mepacrine	abstract[88]|substance[91]	new[88]|new[91]	_	_
17-17	2022-2029	analogs	abstract[88]|substance[91]	new[88]|new[91]	_	_
17-18	2030-2031	,	abstract[88]	new[88]	_	_
17-19	2032-2035	and	abstract[88]	new[88]	_	_
17-20	2036-2047	nitrofurans	abstract[88]|substance[92]	new[88]|new[92]	_	_
17-21	2048-2049	,	abstract[88]|substance[92]	new[88]|new[92]	_	_
17-22	2050-2054	such	abstract[88]|substance[92]	new[88]|new[92]	_	_
17-23	2055-2057	as	abstract[88]|substance[92]	new[88]|new[92]	_	_
17-24	2058-2070	furazolidone	abstract[88]|substance[92]|substance	new[88]|new[92]|new	coref	26-1
17-25	2071-2072	(	_	_	_	_

#Text=Figure 1
18-1	2073-2079	Figure	object[94]	new[94]	_	_
18-2	2080-2081	1	object[94]	new[94]	_	_

#Text=) .
19-1	2082-2083	)	_	_	_	_
19-2	2084-2085	.	_	_	_	_

#Text=Metronidazole is the most widely used drug for the treatment of giardiasis globally and it is generally effective and well-tolerated .
20-1	2086-2099	Metronidazole	substance	giv	coref	20-3[96_0]
20-2	2100-2102	is	_	_	_	_
20-3	2103-2106	the	substance[96]	giv[96]	ana	20-15[0_96]
20-4	2107-2111	most	substance[96]	giv[96]	_	_
20-5	2112-2118	widely	substance[96]	giv[96]	_	_
20-6	2119-2123	used	substance[96]	giv[96]	_	_
20-7	2124-2128	drug	substance[96]	giv[96]	_	_
20-8	2129-2132	for	substance[96]	giv[96]	_	_
20-9	2133-2136	the	substance[96]|abstract[97]	giv[96]|new[97]	coref	22-17[123_97]
20-10	2137-2146	treatment	substance[96]|abstract[97]	giv[96]|new[97]	_	_
20-11	2147-2149	of	substance[96]|abstract[97]	giv[96]|new[97]	_	_
20-12	2150-2160	giardiasis	substance[96]|abstract[97]|abstract	giv[96]|new[97]|giv	coref	21-23[107_0]
20-13	2161-2169	globally	_	_	_	_
20-14	2170-2173	and	_	_	_	_
20-15	2174-2176	it	substance	giv	coref	21-17[104_0]
20-16	2177-2179	is	_	_	_	_
20-17	2180-2189	generally	_	_	_	_
20-18	2190-2199	effective	_	_	_	_
20-19	2200-2203	and	_	_	_	_
20-20	2204-2218	well-tolerated	_	_	_	_
20-21	2219-2220	.	_	_	_	_

#Text=However , the United States Food and Drug Administration ( FDA ) has not yet approved this drug for the treatment of Giardia infection because of its toxicity and major side effects , such as seizures , ataxia , peripheral neuropathy , transient myopia , gastric mucosal irritation , sperm damage , and hematuria .
21-1	2221-2228	However	_	_	_	_
21-2	2229-2230	,	_	_	_	_
21-3	2231-2234	the	object[101]	new[101]	_	_
21-4	2235-2241	United	place[100]|object[101]	new[100]|new[101]	coref	25-7[138_100]
21-5	2242-2248	States	place[100]|object[101]	new[100]|new[101]	_	_
21-6	2249-2253	Food	object[101]	new[101]	_	_
21-7	2254-2257	and	_	_	_	_
21-8	2258-2262	Drug	organization[102]	new[102]	appos	21-11[0_102]
21-9	2263-2277	Administration	organization[102]	new[102]	_	_
21-10	2278-2279	(	_	_	_	_
21-11	2280-2283	FDA	organization	giv	coref	22-14[122_0]
21-12	2284-2285	)	_	_	_	_
21-13	2286-2289	has	_	_	_	_
21-14	2290-2293	not	_	_	_	_
21-15	2294-2297	yet	_	_	_	_
21-16	2298-2306	approved	_	_	_	_
21-17	2307-2311	this	substance[104]	giv[104]	coref	27-7[157_104]
21-18	2312-2316	drug	substance[104]	giv[104]	_	_
21-19	2317-2320	for	substance[104]	giv[104]	_	_
21-20	2321-2324	the	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-21	2325-2334	treatment	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-22	2335-2337	of	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-23	2338-2345	Giardia	substance[104]|abstract[105]|object|abstract[107]	giv[104]|new[105]|giv|giv[107]	coref|coref	22-20[0_107]|22-20[0_107]
21-24	2346-2355	infection	substance[104]|abstract[105]|abstract[107]	giv[104]|new[105]|giv[107]	_	_
21-25	2356-2363	because	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-26	2364-2366	of	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-27	2367-2370	its	substance[104]|abstract[105]|abstract[108]	giv[104]|new[105]|new[108]	_	_
21-28	2371-2379	toxicity	substance[104]|abstract[105]|abstract[108]	giv[104]|new[105]|new[108]	_	_
21-29	2380-2383	and	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-30	2384-2389	major	substance[104]|abstract[105]|abstract[109]	giv[104]|new[105]|new[109]	coref	24-10[131_109]
21-31	2390-2394	side	substance[104]|abstract[105]|abstract[109]	giv[104]|new[105]|new[109]	_	_
21-32	2395-2402	effects	substance[104]|abstract[105]|abstract[109]	giv[104]|new[105]|new[109]	_	_
21-33	2403-2404	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-34	2405-2409	such	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-35	2410-2412	as	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-36	2413-2421	seizures	substance[104]|abstract[105]|event	giv[104]|new[105]|new	_	_
21-37	2422-2423	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-38	2424-2430	ataxia	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-39	2431-2432	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-40	2433-2443	peripheral	substance[104]|abstract[105]|object[111]	giv[104]|new[105]|new[111]	_	_
21-41	2444-2454	neuropathy	substance[104]|abstract[105]|object[111]	giv[104]|new[105]|new[111]	_	_
21-42	2455-2456	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-43	2457-2466	transient	substance[104]|abstract[105]|abstract[112]	giv[104]|new[105]|new[112]	_	_
21-44	2467-2473	myopia	substance[104]|abstract[105]|abstract[112]	giv[104]|new[105]|new[112]	_	_
21-45	2474-2475	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-46	2476-2483	gastric	substance[104]|abstract[105]|abstract|abstract[114]	giv[104]|new[105]|new|new[114]	_	_
21-47	2484-2491	mucosal	substance[104]|abstract[105]|abstract[114]	giv[104]|new[105]|new[114]	_	_
21-48	2492-2502	irritation	substance[104]|abstract[105]|abstract[114]	giv[104]|new[105]|new[114]	_	_
21-49	2503-2504	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-50	2505-2510	sperm	substance[104]|abstract[105]|substance|abstract[116]	giv[104]|new[105]|new|new[116]	_	_
21-51	2511-2517	damage	substance[104]|abstract[105]|abstract[116]	giv[104]|new[105]|new[116]	_	_
21-52	2518-2519	,	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-53	2520-2523	and	substance[104]|abstract[105]	giv[104]|new[105]	_	_
21-54	2524-2533	hematuria	substance[104]|abstract[105]|abstract	giv[104]|new[105]|new	_	_
21-55	2534-2535	.	_	_	_	_

#Text=Tinidazole is an N1-position modified 5-nitro imidazole , which has been approved by the FDA for the treatment of giardiasis .
22-1	2536-2546	Tinidazole	substance	new	coref	22-3[121_0]
22-2	2547-2549	is	_	_	_	_
22-3	2550-2552	an	substance[121]	giv[121]	_	_
22-4	2553-2564	N1-position	abstract|substance[121]	new|giv[121]	_	_
22-5	2565-2573	modified	substance[121]	giv[121]	_	_
22-6	2574-2581	5-nitro	organization|substance[121]	new|giv[121]	_	_
22-7	2582-2591	imidazole	substance[121]	giv[121]	_	_
22-8	2592-2593	,	_	_	_	_
22-9	2594-2599	which	_	_	_	_
22-10	2600-2603	has	_	_	_	_
22-11	2604-2608	been	_	_	_	_
22-12	2609-2617	approved	_	_	_	_
22-13	2618-2620	by	_	_	_	_
22-14	2621-2624	the	organization[122]	giv[122]	_	_
22-15	2625-2628	FDA	organization[122]	giv[122]	_	_
22-16	2629-2632	for	_	_	_	_
22-17	2633-2636	the	abstract[123]	giv[123]	coref	28-14[161_123]
22-18	2637-2646	treatment	abstract[123]	giv[123]	_	_
22-19	2647-2649	of	abstract[123]	giv[123]	_	_
22-20	2650-2660	giardiasis	abstract[123]|abstract	giv[123]|giv	coref	28-17
22-21	2661-2662	.	_	_	_	_

#Text=Nitazoxanide ( NTZ ) belongs to an emerging class of 5-nitrothiazole compounds with potential antigiardial activity .
23-1	2663-2675	Nitazoxanide	substance	new	_	_
23-2	2676-2677	(	_	_	_	_
23-3	2678-2681	NTZ	place	new	coref	24-4
23-4	2682-2683	)	_	_	_	_
23-5	2684-2691	belongs	_	_	_	_
23-6	2692-2694	to	_	_	_	_
23-7	2695-2697	an	abstract[127]	new[127]	_	_
23-8	2698-2706	emerging	abstract[127]	new[127]	_	_
23-9	2707-2712	class	abstract[127]	new[127]	_	_
23-10	2713-2715	of	abstract[127]	new[127]	_	_
23-11	2716-2731	5-nitrothiazole	abstract[127]|substance[128]	new[127]|new[128]	_	_
23-12	2732-2741	compounds	abstract[127]|substance[128]	new[127]|new[128]	_	_
23-13	2742-2746	with	abstract[127]|substance[128]	new[127]|new[128]	_	_
23-14	2747-2756	potential	abstract[127]|substance[128]|abstract[129]	new[127]|new[128]|new[129]	_	_
23-15	2757-2769	antigiardial	abstract[127]|substance[128]|abstract[129]	new[127]|new[128]|new[129]	_	_
23-16	2770-2778	activity	abstract[127]|substance[128]|abstract[129]	new[127]|new[128]|new[129]	_	_
23-17	2779-2780	.	_	_	_	_

#Text=However , although NTZ is generally well tolerated , some adverse effects such as abdominal pain , diarrhea , and nausea limit the safe use for human beings .
24-1	2781-2788	However	_	_	_	_
24-2	2789-2790	,	_	_	_	_
24-3	2791-2799	although	_	_	_	_
24-4	2800-2803	NTZ	substance	giv	_	_
24-5	2804-2806	is	_	_	_	_
24-6	2807-2816	generally	_	_	_	_
24-7	2817-2821	well	_	_	_	_
24-8	2822-2831	tolerated	_	_	_	_
24-9	2832-2833	,	_	_	_	_
24-10	2834-2838	some	abstract[131]	giv[131]	coref	26-4[145_131]
24-11	2839-2846	adverse	abstract[131]	giv[131]	_	_
24-12	2847-2854	effects	abstract[131]	giv[131]	_	_
24-13	2855-2859	such	abstract[131]	giv[131]	_	_
24-14	2860-2862	as	abstract[131]	giv[131]	_	_
24-15	2863-2872	abdominal	abstract[131]|abstract[132]	giv[131]|giv[132]	_	_
24-16	2873-2877	pain	abstract[131]|abstract[132]	giv[131]|giv[132]	_	_
24-17	2878-2879	,	abstract[131]	giv[131]	_	_
24-18	2880-2888	diarrhea	abstract[131]|abstract	giv[131]|giv	_	_
24-19	2889-2890	,	abstract[131]	giv[131]	_	_
24-20	2891-2894	and	abstract[131]	giv[131]	_	_
24-21	2895-2901	nausea	abstract[131]|event	giv[131]|new	_	_
24-22	2902-2907	limit	abstract[131]	giv[131]	_	_
24-23	2908-2911	the	abstract[135]	new[135]	ana	25-12[0_135]
24-24	2912-2916	safe	abstract[135]	new[135]	_	_
24-25	2917-2920	use	abstract[135]	new[135]	_	_
24-26	2921-2924	for	abstract[135]	new[135]	_	_
24-27	2925-2930	human	abstract[135]|person[136]	new[135]|giv[136]	_	_
24-28	2931-2937	beings	abstract[135]|person[136]	new[135]|giv[136]	_	_
24-29	2938-2939	.	_	_	_	_

#Text=Mepacrine is no longer available in the United States , and it is being replaced in most of its applications with safer and more specific drugs .
25-1	2940-2949	Mepacrine	substance	new	_	_
25-2	2950-2952	is	_	_	_	_
25-3	2953-2955	no	_	_	_	_
25-4	2956-2962	longer	_	_	_	_
25-5	2963-2972	available	_	_	_	_
25-6	2973-2975	in	_	_	_	_
25-7	2976-2979	the	place[138]	giv[138]	_	_
25-8	2980-2986	United	place[138]	giv[138]	_	_
25-9	2987-2993	States	place[138]	giv[138]	_	_
25-10	2994-2995	,	_	_	_	_
25-11	2996-2999	and	_	_	_	_
25-12	3000-3002	it	abstract	giv	ana	25-19
25-13	3003-3005	is	_	_	_	_
25-14	3006-3011	being	_	_	_	_
25-15	3012-3020	replaced	_	_	_	_
25-16	3021-3023	in	_	_	_	_
25-17	3024-3028	most	abstract[141]	new[141]	_	_
25-18	3029-3031	of	abstract[141]	new[141]	_	_
25-19	3032-3035	its	abstract|abstract[141]	giv|new[141]	_	_
25-20	3036-3048	applications	abstract[141]	new[141]	_	_
25-21	3049-3053	with	abstract[141]	new[141]	_	_
25-22	3054-3059	safer	abstract[141]|substance[142]	new[141]|giv[142]	coref	28-11[160_142]
25-23	3060-3063	and	abstract[141]|substance[142]	new[141]|giv[142]	_	_
25-24	3064-3068	more	abstract[141]|substance[142]	new[141]|giv[142]	_	_
25-25	3069-3077	specific	abstract[141]|substance[142]	new[141]|giv[142]	_	_
25-26	3078-3083	drugs	abstract[141]|substance[142]	new[141]|giv[142]	_	_
25-27	3084-3085	.	_	_	_	_

#Text=Furazolidone also has serious side effects , such as gastrointestinal disturbances , hemolytic anemia , disulfiram-like reactions to alcohol , and hypersensitivity reactions , as well as evidence of tumorigenicity in rodent studies .
26-1	3086-3098	Furazolidone	substance	giv	_	_
26-2	3099-3103	also	_	_	_	_
26-3	3104-3107	has	_	_	_	_
26-4	3108-3115	serious	abstract[145]	giv[145]	_	_
26-5	3116-3120	side	abstract|abstract[145]	new|giv[145]	_	_
26-6	3121-3128	effects	abstract[145]	giv[145]	_	_
26-7	3129-3130	,	abstract[145]	giv[145]	_	_
26-8	3131-3135	such	abstract[145]	giv[145]	_	_
26-9	3136-3138	as	abstract[145]	giv[145]	_	_
26-10	3139-3155	gastrointestinal	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
26-11	3156-3168	disturbances	abstract[145]|abstract[146]	giv[145]|new[146]	_	_
26-12	3169-3170	,	abstract[145]	giv[145]	_	_
26-13	3171-3180	hemolytic	abstract[145]|abstract[147]	giv[145]|new[147]	_	_
26-14	3181-3187	anemia	abstract[145]|abstract[147]	giv[145]|new[147]	_	_
26-15	3188-3189	,	abstract[145]	giv[145]	_	_
26-16	3190-3205	disulfiram-like	abstract[145]|event[148]	giv[145]|new[148]	_	_
26-17	3206-3215	reactions	abstract[145]|event[148]	giv[145]|new[148]	_	_
26-18	3216-3218	to	abstract[145]|event[148]	giv[145]|new[148]	_	_
26-19	3219-3226	alcohol	abstract[145]|event[148]|substance	giv[145]|new[148]|new	_	_
26-20	3227-3228	,	abstract[145]	giv[145]	_	_
26-21	3229-3232	and	abstract[145]	giv[145]	_	_
26-22	3233-3249	hypersensitivity	abstract[145]|abstract|abstract[151]	giv[145]|new|new[151]	_	_
26-23	3250-3259	reactions	abstract[145]|abstract[151]	giv[145]|new[151]	_	_
26-24	3260-3261	,	abstract[145]	giv[145]	_	_
26-25	3262-3264	as	abstract[145]	giv[145]	_	_
26-26	3265-3269	well	abstract[145]	giv[145]	_	_
26-27	3270-3272	as	abstract[145]	giv[145]	_	_
26-28	3273-3281	evidence	abstract[145]|abstract[152]	giv[145]|new[152]	_	_
26-29	3282-3284	of	abstract[145]|abstract[152]	giv[145]|new[152]	_	_
26-30	3285-3299	tumorigenicity	abstract[145]|abstract[152]|abstract[153]	giv[145]|new[152]|new[153]	_	_
26-31	3300-3302	in	abstract[145]|abstract[152]|abstract[153]	giv[145]|new[152]|new[153]	_	_
26-32	3303-3309	rodent	abstract[145]|abstract[152]|abstract[153]|animal|abstract[155]	giv[145]|new[152]|new[153]|new|new[155]	_	_
26-33	3310-3317	studies	abstract[145]|abstract[152]|abstract[153]|abstract[155]	giv[145]|new[152]|new[153]|new[155]	_	_
26-34	3318-3319	.	_	_	_	_

#Text=Furthermore , G. lamblia resistance to this drug has also been reported .
27-1	3320-3331	Furthermore	_	_	_	_
27-2	3332-3333	,	_	_	_	_
27-3	3334-3336	G.	abstract[156]	new[156]	_	_
27-4	3337-3344	lamblia	abstract[156]	new[156]	_	_
27-5	3345-3355	resistance	abstract[156]	new[156]	_	_
27-6	3356-3358	to	abstract[156]	new[156]	_	_
27-7	3359-3363	this	abstract[156]|substance[157]	new[156]|giv[157]	_	_
27-8	3364-3368	drug	abstract[156]|substance[157]	new[156]|giv[157]	_	_
27-9	3369-3372	has	_	_	_	_
27-10	3373-3377	also	_	_	_	_
27-11	3378-3382	been	_	_	_	_
27-12	3383-3391	reported	_	_	_	_
27-13	3392-3393	.	_	_	_	_

#Text=Therefore , research focusing on the development of novel , alternative drugs for the treatment of giardiasis is highly desirable .
28-1	3394-3403	Therefore	_	_	_	_
28-2	3404-3405	,	_	_	_	_
28-3	3406-3414	research	abstract	giv	_	_
28-4	3415-3423	focusing	_	_	_	_
28-5	3424-3426	on	_	_	_	_
28-6	3427-3430	the	abstract[159]	new[159]	_	_
28-7	3431-3442	development	abstract[159]	new[159]	_	_
28-8	3443-3445	of	abstract[159]	new[159]	_	_
28-9	3446-3451	novel	abstract[159]	new[159]	_	_
28-10	3452-3453	,	_	_	_	_
28-11	3454-3465	alternative	substance[160]	giv[160]	_	_
28-12	3466-3471	drugs	substance[160]	giv[160]	_	_
28-13	3472-3475	for	substance[160]	giv[160]	_	_
28-14	3476-3479	the	substance[160]|abstract[161]	giv[160]|giv[161]	coref	29-16[167_161]
28-15	3480-3489	treatment	substance[160]|abstract[161]	giv[160]|giv[161]	_	_
28-16	3490-3492	of	substance[160]|abstract[161]	giv[160]|giv[161]	_	_
28-17	3493-3503	giardiasis	substance[160]|abstract[161]|abstract	giv[160]|giv[161]|giv	coref	29-19
28-18	3504-3506	is	_	_	_	_
28-19	3507-3513	highly	_	_	_	_
28-20	3514-3523	desirable	_	_	_	_
28-21	3524-3525	.	_	_	_	_

#Text=In view of these considerations , researchers have designed and synthesized some novel molecules for the treatment of giardiasis , their results are summarized in Table 1 .
29-1	3526-3528	In	_	_	_	_
29-2	3529-3533	view	abstract[163]	new[163]	_	_
29-3	3534-3536	of	abstract[163]	new[163]	_	_
29-4	3537-3542	these	abstract[163]|abstract[164]	new[163]|new[164]	_	_
29-5	3543-3557	considerations	abstract[163]|abstract[164]	new[163]|new[164]	_	_
29-6	3558-3559	,	_	_	_	_
29-7	3560-3571	researchers	person	new	ana	29-21
29-8	3572-3576	have	_	_	_	_
29-9	3577-3585	designed	_	_	_	_
29-10	3586-3589	and	_	_	_	_
29-11	3590-3601	synthesized	_	_	_	_
29-12	3602-3606	some	substance[166]	new[166]	_	_
29-13	3607-3612	novel	substance[166]	new[166]	_	_
29-14	3613-3622	molecules	substance[166]	new[166]	_	_
29-15	3623-3626	for	substance[166]	new[166]	_	_
29-16	3627-3630	the	substance[166]|abstract[167]	new[166]|giv[167]	_	_
29-17	3631-3640	treatment	substance[166]|abstract[167]	new[166]|giv[167]	_	_
29-18	3641-3643	of	substance[166]|abstract[167]	new[166]|giv[167]	_	_
29-19	3644-3654	giardiasis	substance[166]|abstract[167]|abstract	new[166]|giv[167]|giv	_	_
29-20	3655-3656	,	_	_	_	_
29-21	3657-3662	their	person|abstract[170]	giv|new[170]	_	_
29-22	3663-3670	results	abstract[170]	new[170]	_	_
29-23	3671-3674	are	_	_	_	_
29-24	3675-3685	summarized	_	_	_	_
29-25	3686-3688	in	_	_	_	_
29-26	3689-3694	Table	object[171]	new[171]	_	_
29-27	3695-3696	1	object[171]	new[171]	_	_
29-28	3697-3698	.	_	_	_	_
